Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma

INTRODUCTION: Treatment of metastatic renal cell carcinoma (mRCC) has improved with the use of targeted therapies, but bone metastases continue to be negative prognostic factor. METHODS: Patients with mRCC treated with everolimus (EV) or sorafenib (SO) after two previous lines of targeted therapies...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Can Urol Assoc J
Main Authors: Iacovelli, Roberto, Santini, Daniele, Rizzo, Mimma, Felici, Alessandra, Santoni, Matteo, Verzoni, Elena, Masini, Cristina, Massari, Francesco, Calvani, Nicola, Mosca, Alessandra, Procopio, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado em: Canadian Medical Association 2015
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4537338/
https://ncbi.nlm.nih.gov/pubmed/26316911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.2377
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados